Direct transition from rapid-infusion originator to rapid-infusion biosimilar tumor necrosis factor inhibitor in children with inflammatory bowel disease: A case series
American Journal of Health-System Pharmacy · 2024
DOI: 10.1093/ajhp/zxad217 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Health-System Pharmacy, 2024. Verfasst von Blake Rosenthal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital Los Angeles, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Inflammatory Bowel Diseases. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institutes of Health.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Purpose
Biosimilar tumor necrosis factor inhibitors (b-TNFi) reduce healthcare costs and maintain equal efficacy when compared to their originator counterparts (o-TNFi). Current practice is to start patients on a slower standard infusion rate during the initial transition from an o-TNFi to a b-TNFi. There is a knowledge gap around switching from rapid originator infusion to rapid biosimilar infusion in the pediatric inflammatory bowel disease (IBD) population. Summary We present a case series of 8 pediatric patients with IBD who were switched from a rapid-infusion o-TNFi to a rapid-infusion b-TNFi from 2016 through 2022. Our primary interest was safety, which we evaluated based on the occurrence of infusion reactions or need for new premedications within the first 6 months of starting a b-TNFi. We also examined effectiveness through the incidence of IBD-related hospitalizations, TNFi failure, and need for co-medication or dose escalation over the same period. In our cohort, 4 patients had Crohn’s disease and 4 had ulcerative colitis. All patients were switched to a biosimilar for nonmedical reasons. During the follow-up period, no patients had infusion reactions necessitating new premedications, serious adverse events, or medication nonresponse.
Conclusion
Patients who directly transitioned from a rapid-infusion o-TNFi to a rapid-infusion b-TNFi did not experience serious adverse events. Given the fiscal and patient experience advantages of rapid-rate infusions, larger studies are needed to consider a change in practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Children's Hospital Los Angeles, Los Angeles, CA, USA.
- University of California San Francisco, University of California San Francisco Benioff Children's Hospital, San Francisco, CA, USA.
- Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA.
- University of California San Francisco Benioff Children's Hospital Oakland, Oakland, CA, USA.
- University of California San Francisco, University of California San Francisco Benioff Children's Hospital Oakland, Oakland, CA, USA.
Förderung
- NIDDK NIH HHS
- National Institutes of Health
Zitieren
APA
Rosenthal, B., Aulakh, S., Patel, P. V., Wong, J. T., & Ali, S. (2024). Direct transition from rapid-infusion originator to rapid-infusion biosimilar tumor necrosis factor inhibitor in children with inflammatory bowel disease: A case series. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxad217
Vancouver
Rosenthal B, Aulakh S, Patel PV, Wong JT, Ali S. Direct transition from rapid-infusion originator to rapid-infusion biosimilar tumor necrosis factor inhibitor in children with inflammatory bowel disease: A case series. American Journal of Health-System Pharmacy. 2024. doi:10.1093/ajhp/zxad217
BibTeX
@article{Rosenthal2024,
author = {Rosenthal, Blake and Aulakh, Sabreen and Patel, Perseus V and Wong, Jason T and Ali, Sabina},
title = {Direct transition from rapid-infusion originator to rapid-infusion biosimilar tumor necrosis factor inhibitor in children with inflammatory bowel disease: A case series},
journal = {American Journal of Health-System Pharmacy},
year = {2024},
doi = {10.1093/ajhp/zxad217}
}
EUVIMED